Breaking Finance News

Bryan Garnier retained GlaxoSmithKline PLC (LON:GSK) to Buy in a statement released earlier today.

Bryan Garnier has retained GlaxoSmithKline PLC (LON:GSK) to Buy in a statement released on 10/17/2016.

On 10/13/2016, Jefferies International released a statement for GlaxoSmithKline PLC (LON:GSK) bumped up the target price from 1,900.00GBX to 1,950.00GBX that suggested an upside of 0.14%.

Displaying a price of 1,685.75GBX, GlaxoSmithKline PLC (LON:GSK) traded -0.59% lower on the day. The last closing price is up 7.62% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of 1,650.69GBX and a 200-day moving average of 1,561.99GBX. 1,367,645 shares of the stock were exchanged, down from an average trading volume of 7,639,810

Performance Chart

GlaxoSmithKline PLC (LON:GSK)

With a total market value of 0 GBX, GlaxoSmithKline PLC has 52 week low of 1,277.25GBX and a 52 week high of 1,745.56GBX with a P/E ratio of 2,801.67 .

In addition to Bryan Garnier reporting its target price, a total of 24 firms have reported on the stock. The consensus target price is 1,577.33GBX with 3 firms rating the stock a strong buy, 6 firms rating the stock a buy, 17 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.